Daniel Lin, MD
Family Medicine · Philadelphia, PANPI 1073781621
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 111 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 30 manufacturers reported payments, led by Gilead at 35.1% of the total. 2025 is the largest year on record at $602, more than ten times the $59 reported in 2020.
Across 111 payments — averaging $17.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$682
- Exact Sciences$237
- Sumitomo Pharma America, Inc.$169
- Boehringer Ingelheim$92
- Ultragenyx Pharmaceutical Inc.$82
- Novo Nordisk$57
- plus $625 from 24 others
Across 51 payments — averaging $7646.33 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Exelixis Inc.$271K
- AstraZeneca$119K
What the payments were for
- Food & beverage$1,936100%
- Education$80%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 47 | $682 |
| Exact Sciences | 12 | $237 |
| Sumitomo Pharma America, Inc. | 9 | $169 |
| Boehringer Ingelheim | 5 | $92 |
| Ultragenyx Pharmaceutical Inc. | 4 | $82 |
| Novo Nordisk | 3 | $57 |
| AstraZeneca | 3 | $50 |
| Amgen | 2 | $45 |
| ANI Pharmaceuticals, Inc. | 2 | $43 |
| Phathom Pharmaceuticals, Inc. | 2 | $43 |
| AbbVie | 2 | $42 |
| Kowa Pharmaceuticals America, Inc. | 2 | $34 |
| Aurinia Pharma U.S., Inc. | 1 | $30 |
| Regeneron Healthcare Solutions, Inc. | 1 | $28 |
| Novartis | 1 | $25 |
| Bayer | 1 | $24 |
| Pharmacosmos Therapeutics Inc. | 1 | $23 |
| Idorsia Pharmaceuticals US Inc | 1 | $22 |
| Phadia US Inc. | 1 | $22 |
| Xeris Pharmaceuticals, Inc. | 1 | $21 |
| Johnson & Johnson | 1 | $19 |
| Shield Therapeutics Inc | 1 | $19 |
| VBI Vaccine (delaware) Inc. | 1 | $18 |
| Meridian Bioscience Inc. | 1 | $18 |
| Sun Pharmaceutical Industries Inc. | 1 | $18 |
| Lilly USA, LLC | 1 | $18 |
| Paratek Pharmaceuticals, Inc. | 1 | $18 |
| Merck | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $14 |
How this compares
$1,944 in reported general payments places this provider in the 75th percentile of 4,967 family medicine providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JanuviaSitagliptin Phosphate | 475 | $410,910 |
| VascepaIcosapent Ethyl | 382 | $195,663 |
| JardianceEmpagliflozin | 134 | $124,344 |
| EliquisApixaban | 105 | $102,380 |
| LinzessLinaclotide | 171 | $97,785 |
| FarxigaDapagliflozin Propanediol | 62 | $45,713 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 11 | $43,682 |
| GemtesaVibegron | 44 | $36,948 |
| Tenofovir Disoproxil Fumarate | 106 | $36,488 |
| TradjentaLinagliptin | 33 | $30,631 |
| VemlidyTenofovir Alafenamide | 16 | $25,388 |
| RestasisCyclosporine | 36 | $22,543 |
| TrulicityDulaglutide | 17 | $22,204 |
| XareltoRivaroxaban | 27 | $21,668 |
| Fenofibrate | 27 | $17,156 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet Xr | $17 | $425,274494 claims |
| Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat | $92 | $161,702179 claims |
| AbbVieLinzess, Restasis | $42 | $120,328207 claims |
| GileadBiktarvy, Vemlidy | $682 | $69,07027 claims |
| AstraZenecaFarxiga, Brilinta | $50 | $52,66176 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $169 | $36,94844 claims |
| Lilly USA, LLCTrulicity | $18 | $22,20417 claims |
| Johnson & JohnsonXarelto | $19 | $21,66827 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Philadelphia
- Deborah WittPhiladelphia$226K
- Michael AttanasioPhiladelphia$214K
- Jonah MinkPhiladelphia$145K
- Celia EzidiegwuPhiladelphia$118K
- Glenn RosenPhiladelphia$61K
- Jessica DefflerPhiladelphia$56K
- Casey LaffertyPhiladelphia$55K
- Margot SavoyPhiladelphia$31K
- Neil SkolnikJenkintown$904K
- Lisa EspinozaNew Hope$722K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.